– USA, MA – Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies, announced the appointment of Dr. Lou Lange (M.D., Ph.D.) to its Board of Directors, effective immediately, expanding the Board to six members.
“We are pleased to welcome Lou to the Incendia Therapeutics Board,” said Board Chairman, Dr. Michael Kauffman. “Lou brings an accomplished history of guiding early-stage companies to produce innovations that deliver value for both patients and investors. He is a wonderful complement to our outstanding board of directors.”
About Dr. Louis G. Lange
Dr. Lou Lange is a highly successful biotechnology investor and serial entrepreneur with deep experience building companies that have generated scientific breakthroughs and significant value for patients and investors. Since 2009, Dr. Lange has served as a General Partner with Asset Management Ventures, Inc., a venture capital firm investing in early-stage digital health, technology, and life sciences companies. Dr. Lange focuses on healthcare innovation, investing in more than 50 companies.
“Incendia’s compelling science offers an opportunity to deliver a new generation of treatments that improve outcomes for patients with solid cancers,” said Dr. Lou Lange. “I look forward to working with my colleagues on the Board to help Incendia realize its full potential.”
About Incendia Therapeutics
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that reengineer the tumor microenvironment to improve cancer outcomes. The company’s approach targets immune-excluded solid tumors, an identifiable, prevalent tumor phenotype with high treatment relapse rates. By breaking down barriers in the TME, immune cells can reach tumors and improve treatment outcomes in solid cancers. The Company’s most advanced investigational therapeutic, PRTH-101, is in a Phase 1c clinical trial for the treatment of patients with advanced solid tumors. The Company is targeting initiation of Phase 2 in 2H2025.
For more: https://www.incendiatx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.